EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?

N S H Xander, B Leeneman, A-M C Dingemans, W E Fiets, W K de Jong, N E M Uyl, A N M Wymenga, A K L Reyners, C A Uyl-de Groot

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von N S H Xander und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 30…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Kwaliteitsgelden Medisch Specialisten.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Dutch Committee for the Evaluation of Oncological Agents (cieBOM) assesses the clinical benefit of systemic anti-cancer treatments (SACTs). For SACTs tested in non-randomized trials (NRTs), cieBOM primarily utilizes response-related thresholds as assessment criteria. As sufficiency of NRT-based evidence for benefit assessments is questionable, this study investigated whether and how NRTs can be used to assess the clinical benefit of new SACTs initially appraised by cieBOM based on randomized controlled trials (RCTs). METHODS: Using the RCTs underpinning cieBOM recommendations issued between 2015 and 2017, we searched for matching NRTs and applied the NRT-related assessment criteria by cieBOM to them. We then compared the assessment outcomes to the respective RCT-based cieBOM recommendations. Further, we investigated how the assessments would change when applying different response-related thresholds and adding a progression-free survival (PFS) threshold. RESULTS: For 13 of the 37 eligible recommendations, a matching NRT was found. Two treatments were assessed positively and six negatively; five treatments were non-assessable. Two positive recommendations matched a positive NRT-based assessment; one matching negative assessment was found, and one treatment could not be assessed based on either trial results. Adding a > 6 months PFS threshold decreased the number of non-assessable NRTs (five to two). CONCLUSIONS: Limited publications and inconsistent data reporting hampered the viability of NRTs for clinical benefit assessments of SACTs beyond the scope of rare indications. Further, response-related assessment criteria alone might not fully grasp the clinical benefit of novel SACTs. NRT-based assessments should be considered with caution due to uncertainty of the trial results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansAntineoplastic AgentsClinical Trials as TopicRandomized Controlled Trials as TopicProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

CancerClinical value assessmentComparisonNon-randomized trialRandomized controlled trial

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA Rotterdam, the Netherlands; Erasmus Centre for Health Economics…
  • Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
  • Department of Medical Oncology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, the Netherlands.
  • Department of Pulmonology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
  • Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA Rotterdam, the Netherlands.
  • Department of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, the Netherlands.

Förderung

  • Stichting Kwaliteitsgelden Medisch Specialisten

Zitieren

APA

Xander, N. S. H., Leeneman, B., Dingemans, A. C., Fiets, W. E., de Jong, W. K., Uyl, N. E. M., Wymenga, A. N. M., Reyners, A. K. L., & Uyl-de Groot, C. A. (2024). Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114262

Vancouver

Xander NSH, Leeneman B, Dingemans AC, Fiets WE, de Jong WK, Uyl NEM, et al. Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114262

BibTeX
@article{Xander2024,
  author = {Xander, N S H and Leeneman, B and Dingemans, A-M C and Fiets, W E and de Jong, W K and Uyl, N E M and Wymenga, A N M and Reyners, A K L and Uyl-de Groot, C A},
  title = {Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114262}
}
Kostenlos starten →